Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02763124 · ClinicalTrials.gov registry record · NA

Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions

A NA study of Astigmatism, sponsored by Gainesville Eye Associates.

Completed
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT02763124: Completed NA study of Astigmatism, sponsored by Gainesville Eye Associates.

NCT02763124 is a NA study of Astigmatism that has completed, run by Gainesville Eye Associates. The registered enrollment target is 18 participants, below the 106-participant average among 31 other Astigmatism trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02763124, a NA study of Astigmatism, has completed, sponsored by Gainesville Eye Associates.

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

To assess the effectiveness of the Verion-LenSx guided arcuate incision technique to reduce astigmatism in a pseudophakic population.

Primary Outcome

Uncorrected monocular distance visual acuity, measured on a logMAR scale, (logarithm of the Minimum Angle of Resolution) which is a measure of visual acuity in which the smaller values indicate better visual acuity.

Conditions Studied

Interventions

  • PROCEDURE Verion-LenSx

Study Locations (1)

Georgia

  • Gainesville Eye Associates - Gainesville

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2016-05
Est. Completion 2016-10
Phase NA
Gainesville Eye Associates

9 total trials

What the finished NCT02763124 record still lists

NCT02763124 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 106-participant average among 31 other Astigmatism trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Astigmatism appearing as the primary indexed condition, and to 1 intervention - of which Verion-LenSx is the first listed.

NCT02763124 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT02763124 about?

NCT02763124 is a clinical study titled "Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions". To assess the effectiveness of the Verion-LenSx guided arcuate incision technique to reduce astigmatism in a pseudophakic population.

What is the current status of trial NCT02763124?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2016-05. Estimated completion is 2016-10.

What conditions does trial NCT02763124 study?

This clinical trial studies the following conditions: Astigmatism.

What interventions are being tested in trial NCT02763124?

The interventions under investigation include: Verion-LenSx (PROCEDURE).

Who is sponsoring clinical trial NCT02763124?

This trial is sponsored by Gainesville Eye Associates, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02763124 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Astigmatism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02763124's enrollment target sits among peer trials

18 30th of 31 higher than 1 of 31 other Astigmatism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Astigmatism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02763124, the US trial registry maintained by the National Library of Medicine. NCT02763124 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.